The Society of Behavioral Medicine (SBM) supports the United States Preventive Services Task Force (USPSTF) recommendation of low-dose computed tomography (LDCT) screening of the chest for eligible populations to reduce lung cancer mortality. SBM also encourages health care providers and policy makers to support: (1) integration of evidence-based tobacco treatment as an essential component of LDCT-based lung cancer screening; (2) expanded access to high-quality LDCT-based screening among underserved high-risk populations; and (3) incorporation of shared decision making as a clinical platform to facilitate consultations and engagement with individuals at high risk for lung cancer. Individuals should receive consultations about the potential benefits and harms associated with participation in a lung cancer screening program.

Background

Lung cancer mortality claims more lives than breast, colorectal, and prostate cancers combined. Based on results from the landmark National Lung Screening Trial (NLST), lung cancer screening with LDCT has been shown to reduce lung cancer mortality. Current recommendations from the USPSTF include screening for adults who are 55-80 years of age; are asymptomatic; currently smoke, or quit within the last 15 years; have a 30 pack-year smoking history (e.g., smoked at least one pack a day for 30 years or two packs a day for 15 years); and do not have other medical conditions that would preclude benefitting from screening.

Despite recent public policies establishing coverage for lung cancer screening among high-risk populations, lung cancer screening awareness, access, and adherence remain extremely low, particularly among underserved populations.

Integration of Evidence-Based Tobacco Treatment

Tobacco abstinence remains the primary method of lung cancer prevention, and evidence-based guidelines for treating tobacco dependence exist. Because adults interested in lung cancer screening are concerned about their lung cancer risk, integrating evidence-based tobacco treatments and resources within screening programs capitalizes on this “teachable moment.” Such interventions within the framework of lung cancer screening programs can extend the benefit and cost-effectiveness of screening.

Special Considerations for Underserved Populations at High Risk

Regrettably, large health disparities remain a nearly endemic aspect of lung cancer epidemiology. The disproportionate burden of lung cancer incidence and mortality largely tracks disparities associated with higher tobacco use among individuals with fewer socioeconomic resources; some racial/ethnic minority groups; individuals residing in rural areas; the lesbian, gay, bisexual, transgender, and questioning community; and individuals with psychiatric comorbidity. Efforts to implement high-quality lung cancer screening should incorporate targeted efforts to reach underserved populations that experience an unequal burden of lung cancer. Efforts should be targeted in terms of public awareness campaigns as well as access to high-quality lung cancer screening programs in local community settings.
Shared Decision Making
With the unprecedented decision to require documentation of shared decision making for lung cancer screening as a prerequisite for coverage, the Centers for Medicare & Medicaid Services highlighted an important aspect of the screening process. Despite its demonstrated benefits, individuals seeking LDCT-based lung cancer screening should also be informed of potential harms, including false-positive results, radiation exposure, significant incidental findings, overdiagnosis, and adverse psychological effects, specifically for patients who receive an indeterminate screening result.

Summary and Recommendations
SBM supports a shared decision making model and integration of evidence-based tobacco treatment in the context of LDCT-based lung cancer screening for eligible, informed adults.

Recommendations for Health Care Providers
1. Integrate evidence-based tobacco treatment in LDCT-based lung cancer screening protocols.
2. Consider structural barriers that impact screening access, uptake, and subsequent adherence, and develop approaches to reach underserved high-risk populations.
3. Engage in shared decision making with LDCT-seeking patients, communicating and exploring the potential benefits, harms, and uncertainties of screening to ensure informed uptake of services.

Recommendations for Policymakers
1. Support evidence-based tobacco treatment approaches, including combined pharmacological and behavioral programs integrated within lung cancer screening programs to help individuals achieve and/or maintain smoking cessation.
2. Expand resource capacity for lung cancer screening implementation within federally qualified health centers and other community health and medical centers that provide health care to a large proportion of patients at elevated risk for lung cancer to ensure access to high-quality screening services.
3. Reinforce high-value care, not high-utilization care, including efforts to screen the right people (i.e., eligible, informed, and committed), not simply more people.
4. Increase funding for research to include the following:
   a. Implementation science to inform optimal clinical operations, including exploration of efforts to promote adherence, understand infrastructure requirements, and manage pulmonary nodules and incidental findings.
   b. Public awareness efforts and patient navigation strategies that promote patient engagement and accurate understanding of the benefits, harms, and uncertainties of screening.
   c. Continued exploration of the benefits, harms, and overall effectiveness of LDCT-based lung cancer screening among underserved populations, including those minimally represented in the NLST pivotal trial.

Endorsements

Acknowledgements
The authors wish to gratefully acknowledge the expert review provided by the Society of Behavioral Medicine’s Health Policy Committee and Cancer Special Interest Group.

Manuscript authors were supported, in part, by the National Institutes of Health’s National Cancer Institute: grant numbers U54CA202995, U54CA202997, and U54CA203000. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
References


